Economic Challenges Hit Edwards Lifesciences Q3 Earnings, Guidance Lags Wall Street Estimates

  • Edwards Lifesciences Corp EW reported Q3 adjusted EPS of $0.61, up 13% Y/Y, missing the Wall Street consensus of $0.62.
  • The company saw persistent U.S. hospital staffing shortages and COVID headwinds in Japan affect its TAVR sales. 
  • Edwards' TAVR sales only grew 1% Y/Y in Q3, reaching $862 million. In the U.S., Edwards' TAVR procedures increased in the mid-single digits versus the prior year.
  • Q3 sales reached $1.32 billion, up 1% (+7% on constant currency), slightly below the consensus of $1.33.
  • Edwards Lifesciences regulatory wins during Q3 included FDA approval and the CE Mark of its Pascal Precision system for patients with degenerative mitral regurgitation (DMR)
  • Guidance: Edwards Lifesciences suspect that U.S. hospital staffing challenges and a strong U.S. dollar will persist. 
  • The company revised FY22 sales guidance at the low end of the company's previous range of $5.35-$5.55 billion, compared to the consensus of $5.47 billion. 
  • It projects an FY22 adjusted EPS of $2.40-$2.50, down from the previous range of $2.50-$2.65 and the consensus of $2.51.
  • For Q4, Edwards expects reported sales and adjusted EPS to be similar to the third quarter.
  • Price Action: EW shares are down 15.9% at $72.57 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!